# BeOne Medicines — Full List of Presentations at EHA 2026
*2026 European Hematology Association (EHA) Congress, June 11–14, Stockholm*

### Zanubrutinib

| # | Abstract Title | Presentation Details | Session | Date/Time | Lead Author |
|---|---|---|---|---|---|
| 1 | Long-term follow-up for safety and efficacy of zanubrutinib in elderly (≥80 years) treatment naïve CLL/SLL patients, including those with del(17p): Subgroup analysis from the SEQUOIA trial | Publication PS1703 | Poster Session 2 | June 13, 2026, 6:45–7:45 PM CEST | Alessandra Tedeschi |
| 2 | Subsequent therapies and time to second progression-free survival events in chronic lymphocytic leukemia/small lymphocytic lymphoma previously treated with zanubrutinib or bendamustine-rituximab | Publication PF601 | Poster Session 1 | June 12, 2026, 6:45–7:45 PM CEST | Mazyar Shadman |
| 3 | Zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL): Implications for interpreting fixed-duration treatment outcomes from CLL17 | Publication PS1718 | Poster Session 2 | June 13, 2026, 6:45–7:45 PM CEST | Talha Munir |
| 4 | Associations between ECOG performance status and patient-reported outcomes in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: Post hoc analysis from the ALPINE trial | Publication PS2492 | Poster Session 2 | June 13, 2026, 6:45–7:45 PM CEST | Nicole Lamanna |
| 5 | A longitudinal analysis of patients with CLL/SLL with impaired health-related quality of life scores at baseline who were treated with zanubrutinib versus ibrutinib: A post hoc analysis of ALPINE | Publication PF1398 | Poster Session 1 | June 12, 2026, 6:45–7:45 PM CEST | Loic Ysebaert |
| 6 | Real-world zanubrutinib treatment patterns in CLL/SLL among US community oncology patients with prior acalabrutinib therapy | Publication PF618 | Poster Session 1 | June 12, 2026, 6:45–7:45 PM CEST | Jing-Zhou Hou |
| 7 | Patterns of treatment utilization and sequencing across lines of therapy in Waldenström macroglobulinemia: Real-world evidence from the United States | Publication PS2516 | Poster Session 2 | June 13, 2026, 6:45–7:45 PM CEST | Prashant Kapoor |
| 8 | Real-world comparative analysis of treatment discontinuation with covalent Bruton tyrosine kinase inhibitors in first-line chronic lymphocytic leukemia | Publication PS1710 | Poster Session 2 | June 13, 2026, 6:45–7:45 PM CEST | Nakhle Saba |
| 9 | Real-world treatment and survival outcomes for zanubrutinib and acalabrutinib monotherapy among treatment-naïve patients with chronic lymphocytic leukemia in the United States | Publication PF608 | Poster Session 1 | June 12, 2026, 6:45–7:45 PM CEST | Ryan Jacobs |
| 10 | A real-world comparison of treatment and survival outcomes with zanubrutinib and acalabrutinib monotherapy among patients with relapsed or refractory mantle cell lymphoma in the United States | Publication PS2040 | Poster Session 2 | June 13, 2026, 6:45–7:45 PM CEST | Yucai Wang |
| 11 | Clinical outcomes among patients with relapsed/refractory mantle cell lymphoma receiving zanubrutinib or acalabrutinib in real-world practice in the United States | Publication PF958 | Poster Session 1 | June 12, 2026, 6:45–7:45 PM CEST | Javier Munoz |
| 12 | Real-world impact of atrial fibrillation on cardiovascular outcomes and healthcare resource utilization in patients with chronic lymphocytic leukemia | Publication PS2515 | Poster Session 2 | June 13, 2026, 6:45–7:45 PM CEST | Rhys Williams |
| 13 | Treatment burden among patients aged 75 or older with chronic lymphocytic leukemia and small lymphocytic lymphoma | Publication PF605 | Poster Session 1 | June 12, 2026, 6:45–7:45 PM CEST | Daniel Ermann |
| 14 | Real-world effectiveness and safety of zanubrutinib in Waldenström macroglobulinemia: Results from the Belgian WIZARD study | Abstract PB3600 | — | — | Willem Daneels |
| 15 | Real-world experience with zanubrutinib in chronic lymphocytic leukaemia - patient profile, treatment patterns, and safety: Preliminary analysis of French ROZALY study | Abstract PB2898 | — | — | Florian Bouclet |
| 16 | BRUMIZE: Real-world zanubrutinib use and preliminary safety in R/R marginal zone lymphoma in Europe | Abstract PB3632 | — | — | Côme Bommier |
| 17 | Indirect comparison of zanubrutinib vs acalabrutinib and ibrutinib efficacy in patients with treatment-naïve chronic lymphocytic leukemia | Abstract PB2895 | — | — | Mazyar Shadman |
| 18 | Patient-reported outcomes and disease progression in chronic lymphocytic leukemia and small lymphocytic lymphoma: A systematic literature review and gap analysis | Abstract PB2909 | — | — | Loic Ysebaert |
| 19 | Understanding patients' perspectives and preferences regarding first-line chronic lymphocytic leukemia treatment across Europe | Abstract PB2934 | — | — | Lydia Scarfò |
| 20 | Number of deaths avoided with use of zanubrutinib versus ibrutinib for the treatment of chronic lymphocytic leukemia in Europe | Abstract PB2944 | — | — | Talha Munir |
| 21 | Real-world intravenous immunoglobulin utilization in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with venetoclax plus obinutuzumab vs zanubrutinib | Abstract PB2915 | — | — | Nicole Lamanna |
| 22 | Real-world outcomes among Medicare beneficiaries treated with first-line Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia | Abstract PB2901 | — | — | Daniel A. Ermann |
| 23 | Exploring the patient and hematologist preference of treatment characteristics for chronic lymphocytic leukemia: A qualitative study in Europe | Abstract PB4474 | — | — | Lydia Scarfò |

### Sonrotoclax

| # | Abstract Title | Presentation Details | Session | Date/Time | Lead Author |
|---|---|---|---|---|---|
| 1 | First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/*TP53* | Publication S145 | s424 – Prognostication and first line therapy in CLL | June 12, 2026, 17:15–18:30 CEST | Chan Y. Cheah |
| 2 | Updated safety and efficacy of all-oral sonrotoclax + zanubrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including patients with del(17p)/*TP53* | Publication PS1697 | Poster Session 2 | June 13, 2026, 6:45–7:45 PM CEST | Stephen S. Opat |
| 3 | Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib in patients with relapsed/refractory mantle cell lymphoma: Results from a phase 1/1b study | Publication PF933 | Poster Session 1 | June 12, 2026, 6:45–7:45 PM CEST | Jacob D. Soumerai |
| 4 | Phase 1/2 study of sonrotoclax (BGB-11417) monotherapy in Bruton tyrosine kinase inhibitor–pretreated relapsed/refractory mantle cell lymphoma: A Chinese subpopulation analysis | Publication PF961 | Poster Session 1 | June 12, 2026, 6:45–7:45 PM CEST | Yuqin Song |
| 5 | Sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + acalabrutinib in treatment-naive chronic lymphocytic leukemia: A phase 3 randomized trial design (CELESTIAL-TNCLL-2) | Abstract PB2966 | — | — | Mazyar Shadman |
| 6 | Efficacy of sonrotoclax versus pirtobrutinib in post–Bruton tyrosine kinase inhibitor relapsed/refractory mantle cell lymphoma: An indirect comparison | Abstract PB3626 | — | — | Toby A. Eyre |
| 7 | Navigating the post–covalent Bruton tyrosine kinase inhibitor landscape in mantle cell lymphoma: Real-world insights on treatment patterns, discontinuation, and healthcare resource utilization | Abstract PB3617 | — | — | Toby A. Eyre |
| 8 | Risk of tumor lysis syndrome among venetoclax-treated patients with chronic lymphocytic leukemia or mantle cell lymphoma: A real-world study | Abstract PB2896 | — | — | Alessandra Ferrajoli |

### BGB-16673

| # | Abstract Title | Presentation Details | Session | Date/Time | Lead Author |
|---|---|---|---|---|---|
| 1 | BGB-16673, a Bruton tyrosine kinase degrader, in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: A phase 1 CaDAnCe-101 study update | Publication S152 | s449 – Novel therapies in relapsed/refractory CLL | June 14, 2026, 11:00–12:15 CEST | Stephan Stilgenbauer |
| 2 | Bruton tyrosine kinase (BTK) degrader BGB-16673 in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies: Results from the phase 1 CaDAnCe-101 study | Publication PS1693 | Poster Session 2 | June 13, 2026, 6:45–7:45 PM CEST | Irina Mocanu |
| 3 | BGB-16673, a Bruton tyrosine kinase degrader, in patients with relapsed/refractory Waldenström macroglobulinemia: A phase 1 CaDAnCe-101 study update | Publication PS2033 | Poster Session 2 | June 13, 2026, 6:45–7:45 PM CEST | Judith Trotman |
| 4 | BGB-16673, a Bruton tyrosine kinase degrader, has low risk of CYP3A-mediated drug-drug interaction (DDI): Phase 1 absorption, distribution, metabolism, and excretion and DDI study results | Publication PS1711 | Poster Session 2 | June 13, 2026, 6:45–7:45 PM CEST | Judith Trotman |
| 5 | BGB-16673 versus idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: The phase 3 CaDAnCe-302 trial | Abstract PB2925 | — | — | Paolo Ghia |

### Tislelizumab

| # | Abstract Title | Presentation Details | Session | Date/Time | Lead Author |
|---|---|---|---|---|---|
| 1 | Evaluation of PET-CT metrics and pharmacokinetics in adults receiving tislelizumab for relapsed/refractory classical Hodgkin lymphoma: Ancillary analyses of LYSA phase 2 TIRHOL study BGB-A317-210 | Publication PS2028 | Poster Session 2 | June 13, 2026, 6:45–7:45 PM CEST | Hervé Ghesquières |

---
*Source: BeOne Medicines press release, "BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts."*